Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?

Author(s): Christopher R. Lindholm, Corey A. Siegel*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 1 , 2019


Abstract:

Inflammatory bowel disease (IBD) is a chronic inflammatory disease characterized by periodic episodes of flares and remission. Treatment is aimed at healing the bowel, to ultimately decrease hospitalization rates, need for surgeries and overall disability. In more recent years, treatment has transitioned from a reactive approach to a more proactive approach focusing on treating disease earlier and preventing complications. The challenge lies in identifying patients who need more intensive treatment early and trying to determine who will respond to which medications. Biomarkers and clinical activity scoring systems can be used to help guide treatment decisions. However, IBDs are very heterogeneous and the significance of these biomarkers can be difficult to discern on an individual basis. Recently, prognostic tools have been developed to aid in determining a patient’s prognosis as well as their likelihood to respond to different therapies. Despite this progress, clinical trials have not routinely adopted this approach in their study design. Tools for stratification of disease severity and to personalize treatment choices have the potential to improve our studies both by enriching the patient population and further guiding clinical decision making in practice. This review aims to discuss biomarkers, current prognosticating tools, tools that determine response to therapy and how incorporating these into clinical trials will be beneficial.

Keywords: Inflammatory bowel disease, Crohn's disease, ulcerative colitis, prognosis, prognostic factors, chronic inflammatory disease.

[1]
Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn’s disease is improved with early treatment: An analysis of health claims data. Inflamm Bowel Dis 2012; 18(12): 2225-31.
[2]
Rogler G. Top-down or step-up treatment in Crohn’s disease? Dig Dis 2013; 31(1): 83-90.
[3]
Danese S, Fiorino G, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn’s disease. Curr Drug Targets 2014; 15(11): 1056-63.
[4]
Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn’s disease: Towards disease modification trials. Gut 2017; 66(12): 2179-87.
[5]
Colombel J-F, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017; 152(2): 351-361.e5.
[6]
Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease? Ann Gastroenterol 2018; 31(4): 413-24.
[7]
Im JP, Ye BD, Kim YS, Kim JS. Changing treatment paradigms for the management of inflammatory bowel disease. Korean J Intern Med (Korean Assoc Intern Med) 2018; 33(1): 28-35.
[8]
Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2008; 6(11): 1218-24.
[9]
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110(9): 1324-38.
[10]
Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141(4): 1194-201.
[11]
Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet 2018; 390(10114): 2779-89.
[12]
Haritunians T, Taylor KD, Targan SR, et al. Genetic predictors of medically refractory ulcerative colitis. Inflamm Bowel Dis 2010; 16(11): 1830-40.
[13]
Golovics PA, Lovasz BD, Vegh Z, et al. Sa1169 are extraintestinal manifestations associated with disease outcomes in ulcerative colitis? Results from a population-based inception cohort between 2002-2012. Gastroenterology 2015; 148(4): S-246-7.
[14]
Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F, da Costa Pereira A. Clinical prognostic factors for disabling Crohn’s disease: A systematic review and meta-analysis. World J Gastroenterol 2013; 19(24): 3866-71.
[15]
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology 2006; 130(3): 650-6.
[16]
Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn’s disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98(12): 2712-8.
[17]
Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56(10): 1394-403.
[18]
Lichtenstein GR, Targan SR, Dubinsky MC, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn’s disease behavior. Inflamm Bowel Dis 2011; 17(12): 2488-96.
[19]
Cleynen I, González JR, Figueroa C, et al. Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013; 62(11): 1556-65.
[20]
Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015; 47(2): 172-9.
[21]
Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003; 62(6): 527-35.
[22]
Viennois E, Zhao Y, Merlin D. Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine. Inflamm Bowel Dis 2015; 21(10): 2467-74.
[23]
Ji Y, Li X, Zhu Y, Li N, Zhang N, Niu M. Faecal microRNA as a biomarker of the activity and prognosis of inflammatory bowel diseases. Biochem Biophys Res Commun 2018; 503(4): 2443-50.
[24]
Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol 2009; 7(9): 972-980.e2.
[25]
Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: A multicentre inception cohort study. Lancet 2017; 389(10080): 1710-8.
[26]
Reddy BK, Delen D, Agrawal RK. Predicting and explaining inflammation in Crohn’s disease patients using predictive analytics methods and electronic medical record data. Health Informatics J 2018; 1460458217751015.
[27]
Ozaki R, Kobayashi T, Okabayashi S, et al. Histological risk factors to predict clinical relapse in ulcerative colitis with endoscopically normal mucosa. J Crohn’s Colitis 2018; 12(11): 1288-94.
[28]
Solberg IC, Cvancarova M, Vatn MH, Moum B. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn’s Disease (the IBSEN Study). Inflamm Bowel Dis 2014; 20(1): 60-8.
[29]
Takayama T, Okamoto S, Hisamatsu T, et al. Computer-aided prediction of long-term prognosis of patients with ulcerative colitis after cytoapheresis therapy. PLoS One 2015; 10(6): e0131197.
[30]
Lakatos PL, Sipeki N, Kovacs G, et al. Risk Matrix for Prediction of Disease Progression in a Referral Cohort of Patients with Crohn’s Disease. J Crohn’s Colitis 2015; 9(10): 891-8.
[31]
Solberg IC, Høivik ML, Cvancarova M, Moum B. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol 2015; 50(12): 1456-62.
[32]
Siegel CA, Horton H, Siegel LS, et al. Alimentary Pharmacology and Therapeutics A validated web-based tool to display individualised Crohn’s disease predicted outcomes based on clinical, serologic and genetic variables 2016; 43(2): 262-71.
[33]
Dias CC, Rodrigues PP, Coelho R, et al. Development and Validation of Risk Matrices for Crohn’s Disease Outcomes in Patients Submitted to Early Therapeutic Interventions. J Crohn’s Colitis 2016; 11(4): jjw207.
[34]
Park Y, Cheon JH, Park YL, et al. Development of a Novel Predictive Model for the Clinical Course of Crohn’s Disease: Results from the CONNECT Study. Inflamm Bowel Dis 2017; 23(7): 1071-9.
[35]
Waljee AK, Lipson R, Wiitala WL, et al. Predicting Hospitalization and Outpatient Corticosteroid Use in Inflammatory Bowel Disease Patients Using Machine Learning. Inflamm Bowel Dis 2017; 24(1): 45-53.
[36]
Siegel CA, Whitman CB, Spiegel BMR, et al. Development of an index to define overall disease severity in IBD. Gut 2018; 67(2): 244-54.
[37]
Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol 2016; 14(3): 348-354.e17.
[38]
Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther 2008; 28(10): 1221-9.
[39]
Sipponen T, Björkesten C-GA, Färkkilä M, Nuutinen H, Savilahti E, Kolho K-L. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol 2010; 45(3): 325-31.
[40]
Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: A predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004; 39(10): 1017-20.
[41]
Murdoch T, O’Donnell S, Silverberg MS, Panaccione R. Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review. Can J Gastroenterol Hepatol 2015; 29(4): 203-8.
[42]
Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11(8): 707-12.
[43]
Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001; 120(6): 1347-55.
[44]
Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: A national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol 2017; 52(6-7): 722-9.
[45]
Shelton E, Allegretti JR, Stevens B, et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis 2015; 21(12): 2879-85.
[46]
Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol 2018; 5(1): e000208.
[47]
Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther 2017; 45(9): 1232-43.
[48]
Saito K, Katsuno T, Nakagawa T, et al. Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther 2012; 36(8): 744-54.
[49]
Billiet T, Papamichael K, de Bruyn M, et al. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn’s Disease. J Crohn’s Colitis 2015; 9(12): 1120-6.
[50]
Barber GE, Yajnik V, Khalili H, et al. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn’s Disease. Am J Gastroenterol 2016; 111(12): 1816-22.
[51]
Tew GW, Hackney JA, Gibbons D, et al. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology 2016; 150(2): 477-87.e9.
[52]
Dulai PS, Boland BS, Singh S, et al. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease. Gastroenterology 2018; 155(3): 687-695.e10.
[53]
Telesco SE, Brodmerkel C, Zhang H, et al. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology 2018; 155(4): 1008-1011.e8.
[54]
Burke KE, Khalili H, Garber JJ, et al. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflamm Bowel Dis 2018; 24(8): 1840-8.
[55]
Waljee AK, Liu B, Sauder K, et al. Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis. Aliment Pharmacol Ther 2018; 47(6): 763-72.
[56]
Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146(1): 96-109.e1.
[57]
Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: A phase 2a study. Gastroenterology 2017; 153(1): 77-86.e6.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 1
Year: 2019
Page: [64 - 68]
Pages: 5
DOI: 10.2174/1381612825666190312113935
Price: $58

Article Metrics

PDF: 16
HTML: 4
EPUB: 1
PRC: 1

Special-new-year-discount